RTE60 / Retatrutide (60 mg Vial) Dosage Protocol
RTE60 Blend combines a GHRH analog (5 mg) with a selective GHRP (5 mg) in a single vial — pairing GH-releasing-hormone stimulation with growth-hormone-secretagogue amplification for synergistic pulsatile GH release.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
The same phase 2 and phase 3 schedules converted for a 60 mg vial
Phase 2 Trial Schedule (3 mL = 20 mg/mL)
| Study Phase | Weekly Dose | U-100 Units | Volume |
|---|---|---|---|
| Weeks 1 to 4 | 2 mg | 10 units | 0.1 mL |
| Weeks 5 to 8 | 4 mg | 20 units | 0.2 mL |
| Weeks 9 to 12 | 8 mg | 40 units | 0.4 mL |
| Weeks 13+ | 12 mg | 60 units | 0.6 mL |
Frequency: Once weekly by subcutaneous administration. This table shows the lower-start 12 mg arm from the 48-week phase 2 obesity trial. The study also evaluated separate 1 mg, 4 mg, and 8 mg target arms. Every listed amount fits within one 1 mL syringe at this concentration.
Phase 3 Trial Schedule (3 mL = 20 mg/mL)
| Study Phase | Weekly Dose | U-100 Units | Volume |
|---|---|---|---|
| Weeks 1 to 4 | 2 mg | 10 units | 0.1 mL |
| Weeks 5 to 8 | 4 mg | 20 units | 0.2 mL |
| Weeks 9 to 12 | 6 mg | 30 units | 0.3 mL |
| Weeks 13 to 16 | 9 mg | 45 units | 0.45 mL |
| Weeks 17+ | 12 mg | 60 units | 0.6 mL |
Frequency: Once weekly by subcutaneous administration. The phase 3 program began at 2 mg and increased every four weeks until the assigned 4 mg, 9 mg, or 12 mg target was reached. Every listed amount fits within one 1 mL syringe at this concentration.
Reconstitution Steps
- Clean the vial stopper and gather the sterile supplies required by the research procedure.
- Add 3 mL bacteriostatic water slowly down the vial wall.
- Gently swirl or roll until dissolved. Do not shake.
- Label the vial 20 mg/mL with the preparation date and follow the documented refrigerated storage period.
The weekly amounts remain identical across the Retatrutide family. The 60 mg vial changes only the concentration, U-100 units, volume, and supply calculations.
Supplies Needed
Straightforward 12-week and 24-week planning for a 60 mg vial at 20 mg/mL.
| Item | Phase 2, 12 weeks | Phase 2, 24 weeks | Phase 3, 12 weeks | Phase 3, 24 weeks |
|---|---|---|---|---|
| Retatrutide vials (60 mg each) | Minimum 1 vial (56 mg required). | Minimum 4 vials (200 mg required). | Minimum 1 vial (48 mg required). | Minimum 3 vials (180 mg required). |
| U-100 insulin syringes (1 mL capacity) | 12 new syringes. | 24 new syringes. | 12 new syringes. | 24 new syringes. |
| Bacteriostatic water (10 mL bottles) | 1 bottle by volume (3 mL required). | 2 bottles by volume (12 mL required). | 1 bottle by volume (3 mL required). | 1 bottle by volume (9 mL required). |
| Alcohol swabs | 24 swabs minimum; 1 box of 100 covers the calculation. | 48 swabs minimum; 1 box of 100 covers the calculation. | 24 swabs minimum; 1 box of 100 covers the calculation. | 48 swabs minimum; 1 box of 100 covers the calculation. |
Sharps disposal: One appropriately sized container for used syringes.
Stability planning: Vial and diluent totals are minimum arithmetic quantities. Follow the exact product documentation for sterility, storage, handling loss, and discard timing.
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 28 days, protect from light |
Important Notes
How This Works
This blend pairs CJC-1295 without DAC (a GHRH analog) with ipamorelin (a selective GHRP / ghrelin mimetic). The two work through complementary pituitary pathways: CJC-1295 binds GHRH receptors on somatotrophs to trigger GH release; ipamorelin binds GHS-R receptors and amplifies the GHRH-driven pulse.
The combination produces larger GH pulses than either component alone, mimicking the body’s natural pulsatile pattern. Ipamorelin's selectivity (no significant cortisol or prolactin elevation) makes the blend cleaner than older GHRPs like GHRP-2 or GHRP-6.
Potential Benefits & Side Effects
Potential Benefits
- Synergistic GH pulse — larger than either component alone.
- Pulsatile pattern mimics physiological GH rhythm.
- Ipamorelin selectivity avoids cortisol/prolactin spikes.
- Often combined with pre-bed dosing for sleep-quality benefits.
Side Effect Profile
- Injection-site reactions.
- Mild head flushing post-dose.
- Transient hunger increase (ghrelin pathway).
- Mild fluid retention.
Lifestyle Factors
- Avoid eating for 30+ minutes after injection.
- Pre-bed timing aligns with natural overnight GH pulse.
- Resistance training amplifies outcomes.
Injection Technique
- Subcutaneous into abdomen, thigh, or upper arm.
- Rotate sites with each dose.
- 90° angle with short insulin needle.